Biorestorative Therapies Inc (BRTX)

$2.67 -0.09 (-3.26%)
Market Cap 3.69M
Revenue (ttm) 360,000.00
Net Income (ttm) -14.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,955.56%
Debt to Equity Ratio 0.00
Volume 11,600
Avg Vol 20,726
Day's Range N/A - N/A
Shares Out 1.38M
Stochastic %K 4%
Beta 0.83
Analysts Strong Sell
Price Target $160.00

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral di...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 760 8100
Address:
40 Marcus Drive, Suite 1, Melville, United States
MGroup
MGroup Sep. 12 at 4:02 PM
$BRTX with Silva gone, who’s working here ? The preliminary results from BRTX-100 were very encouraging, but who’s running the show ?? And where is Kaos ??
1 · Reply
Dsradoff720
Dsradoff720 Sep. 12 at 10:11 AM
$BRTX the best thing I think now that can happen is they completely shift to ai or something crazy but I assume that would require issuing a massive amount t of shares to the company they would merge with.
0 · Reply
MGroup
MGroup Sep. 11 at 6:26 PM
$BRTX some sort of earnings report 9/14. I would much prefer somebody giving an explanation of what is actually going on
0 · Reply
wren2016
wren2016 Sep. 11 at 4:06 PM
$BRTX Another r/s will never get my money back.
0 · Reply
Dsradoff720
Dsradoff720 Sep. 11 at 2:44 PM
$BRTX Silva is gone? Pretty messed up. If they don’t have a plan this could be really rough. They have active patients and Silvas name is on their parents too I believe. So how does that work? The price isn’t crashing either which is odd so I’m wondering wth is going to happen. Are they going to completely shift? Are they going to fold? We need more info let out.
0 · Reply
Sixty8times
Sixty8times Sep. 10 at 7:15 PM
$BRTX what a pile of crap this has turned out to be. Those of you who were in it early, got smashed with a 4000/1 reverse split and now another reverse split. And that was two years ago. Good luck.
0 · Reply
YouVSYou
YouVSYou Sep. 9 at 7:45 PM
$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 8:09 PM
Today's reverse split results. 3 of 8 closed green today. Part 1 of 2: $AIXI 1 for 7 Previous close $0.4715, $3.3005 split-adjusted Today's high $3.45 (premarket) Today's close $3.26 🔴Down 1.23% $BRTX 1 for 20 Previous close $0.1480, $2.96 split-adjusted Today's high $3.23 Today's close $2.8028 🔴Down 5.31% $CTSO 1 for 20 Previous close $0.3501, $7.002 split-adjusted Today's high $7.44 Today's close $6.85 🔴Down 2.17% $GTBP 1 for 25 Previous close $0.2410, $6.025 split-adjusted Today's high $5.95 Today's close $5.2395 🔴Down 13.04%
1 · Reply
MGroup
MGroup Sep. 8 at 6:04 PM
$BRTX outstanding is 1.4 millionish. Never owned a stock with such a tiny float. This should get real interesting from a technical standpoint. And BRTX-100 is a viabe stem cell product. Seems we forgot about stem cells in biotech. It's all small molecule now days.
1 · Reply
TheBigDawgRoman
TheBigDawgRoman Sep. 8 at 1:53 PM
$BRTX holding at 10 dollars!!
0 · Reply
Latest News on BRTX
BioRestorative Therapies Inc trading halted, news pending

2026-09-04T23:55:36.000Z - 9 days ago

BioRestorative Therapies Inc trading halted, news pending

BioRestorative Therapies announces 1-for-20 reverse stock split

2026-09-02T21:35:08.000Z - 11 days ago

BioRestorative Therapies announces 1-for-20 reverse stock split

BioRestorative Therapies Announces Reverse Stock Split

Sep 2, 2026, 5:27 PM EDT - 11 days ago

BioRestorative Therapies Announces Reverse Stock Split

BioRestorative Therapies completes manufacturing for BRTX-100

2026-06-25T12:20:21.000Z - 2 months ago

BioRestorative Therapies completes manufacturing for BRTX-100

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

Jun 25, 2026, 8:15 AM EDT - 2 months ago

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

BioRestorative Therapies Slides: Corporate presentation

Jun 25, 2026, 7:00 AM EDT - 2 months ago

BioRestorative Therapies Slides: Corporate presentation

BioRestorative Therapies appoints Smith as VP of Biocosmeceuticals Division

2026-06-18T12:31:51.000Z - 2 months ago

BioRestorative Therapies appoints Smith as VP of Biocosmeceuticals Division

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Jun 18, 2026, 8:15 AM EDT - 2 months ago

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

BioRestorative Therapies Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 3 months ago

BioRestorative Therapies Slides: Corporate presentation

BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake

2026-05-27T12:10:07.000Z - 3 months ago

BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

May 27, 2026, 7:45 AM EDT - 3 months ago

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

2026-05-26T16:05:13.000Z - 3 months ago

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

May 26, 2026, 11:00 AM EDT - 3 months ago

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 months ago

BioRestorative Therapies Quarterly report: Q1 2026

BioRestorative Therapies presents preclinical data on MSC exosome proteomics

2026-05-13T18:18:04.000Z - 4 months ago

BioRestorative Therapies presents preclinical data on MSC exosome proteomics

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

May 13, 2026, 11:00 AM EDT - 4 months ago

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100

2026-05-07T17:39:05.000Z - 4 months ago

BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

May 7, 2026, 12:00 PM EDT - 4 months ago

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

Apr 30, 2026, 10:36 AM EDT - 4 months ago

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

BioRestorative Therapies Slides: Corporate presentation

Apr 24, 2026, 7:00 AM EDT - 4 months ago

BioRestorative Therapies Slides: Corporate presentation

BioRestorative Therapies announces partnership with David Goldberg, M.D.

2026-04-21T13:19:35.000Z - 4 months ago

BioRestorative Therapies announces partnership with David Goldberg, M.D.

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

Apr 21, 2026, 8:00 AM EDT - 4 months ago

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

BioRestorative Therapies Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 5 months ago

BioRestorative Therapies Proxy statement: Proxy filing

BioRestorative Therapies announces strategic collaboration with 203 Creates

2026-04-07T14:23:38.000Z - 5 months ago

BioRestorative Therapies announces strategic collaboration with 203 Creates

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Apr 7, 2026, 8:15 AM EDT - 5 months ago

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

BioRestorative Therapies Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 5 months ago

BioRestorative Therapies Proxy statement: Proxy filing

BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital

2026-04-02T12:00:42.000Z - 5 months ago

BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital

BioRestorative Therapies reports blinded data from mesenchymal stem cells trial

2026-03-30T12:53:07.000Z - 5 months ago

BioRestorative Therapies reports blinded data from mesenchymal stem cells trial

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 30, 2026, 8:00 AM EDT - 5 months ago

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

BioRestorative Therapies Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

BioRestorative Therapies Annual report: Q4 2025

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 19, 2026, 8:00 AM EDT - 5 months ago

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

Mar 5, 2026, 8:00 AM EST - 6 months ago

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

BioRestorative Therapies issues letter to shareholders

2026-03-04T13:33:10.000Z - 6 months ago

BioRestorative Therapies issues letter to shareholders

BioRestorative Therapies expands global protection for ThermoStem

2026-02-24T13:45:03.000Z - 6 months ago

BioRestorative Therapies expands global protection for ThermoStem

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Feb 24, 2026, 8:30 AM EST - 6 months ago

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

BioRestorative Announces Closing of $5.0 Million Public Offering

Feb 13, 2026, 8:30 PM EST - 7 months ago

BioRestorative Announces Closing of $5.0 Million Public Offering

BioRestorative Therapies prices $5.0M public offering of common stock at $0.35

2026-02-12T12:50:13.000Z - 7 months ago

BioRestorative Therapies prices $5.0M public offering of common stock at $0.35

BioRestorative Announces Pricing of $5.0 Million Public Offering

Feb 11, 2026, 10:30 PM EST - 7 months ago

BioRestorative Announces Pricing of $5.0 Million Public Offering

BioRestorative Therapies expects to sumbit Phase 3 trial IND in 2H26

2026-02-11T12:40:48.000Z - 7 months ago

BioRestorative Therapies expects to sumbit Phase 3 trial IND in 2H26

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

Feb 11, 2026, 7:30 AM EST - 7 months ago

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100

2026-02-10T13:11:31.000Z - 7 months ago

BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100

BioRestorative Therapies Registration statement: Registration Filing

Feb 10, 2026, 7:00 AM EST - 7 months ago

BioRestorative Therapies Registration statement: Registration Filing

BioRestorative Therapies files to sell 9.71M units

2026-02-09T22:40:19.000Z - 7 months ago

BioRestorative Therapies files to sell 9.71M units

BioRestorative Therapies Registration statement: Registration Filing

Feb 9, 2026, 7:00 AM EST - 7 months ago

BioRestorative Therapies Registration statement: Registration Filing

BioRestorative Therapies Slides: Investor presentation

Nov 22, 2025, 7:00 AM EST - 9 months ago

BioRestorative Therapies Slides: Investor presentation

BioRestorative Therapies Registration statement: Registration Filing

Nov 18, 2025, 7:00 AM EST - 9 months ago

BioRestorative Therapies Registration statement: Registration Filing

BioRestorative Therapies Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioRestorative Therapies Earnings Call Transcript: Q3 2025

BioRestorative Therapies Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioRestorative Therapies Quarterly report: Q3 2025

BioRestorative Therapies Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioRestorative Therapies Earnings release: Q3 2025

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Oct 27, 2025, 7:30 AM EDT - 10 months ago

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

Oct 22, 2025, 9:35 AM EDT - 10 months ago

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

Oct 15, 2025, 9:35 AM EDT - 11 months ago

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

Oct 7, 2025, 9:25 AM EDT - 11 months ago

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Oct 6, 2025, 2:28 PM EDT - 11 months ago

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

BioRestorative Therapies Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q2 2025

BioRestorative Therapies Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Quarterly report: Q2 2025

BioRestorative Therapies Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings release: Q2 2025

BioRestorative Therapies Proxy statement: Proxy Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

BioRestorative Therapies Proxy statement: Proxy Filing

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

BioRestorative Therapies Transcript: Status Update

Jun 18, 2025, 10:50 AM EDT - 1 year ago

BioRestorative Therapies Transcript: Status Update

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Jun 18, 2025, 9:35 AM EDT - 1 year ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

BioRestorative Announces Share Repurchase Program

Jun 17, 2025, 9:25 AM EDT - 1 year ago

BioRestorative Announces Share Repurchase Program

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Jun 13, 2025, 7:45 AM EDT - 1 year ago

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

Jun 9, 2025, 7:45 AM EDT - 1 year ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

BioRestorative Therapies Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q1 2025

BioRestorative Therapies Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Quarterly report: Q1 2025

BioRestorative Therapies Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings release: Q1 2025

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

May 13, 2025, 9:15 AM EDT - 1 year ago

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

May 7, 2025, 9:15 AM EDT - 1 year ago

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 15, 2025, 8:30 AM EDT - 1 year ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Apr 10, 2025, 9:15 AM EDT - 1 year ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

BioRestorative Therapies Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q4 2024

BioRestorative Therapies Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Annual report: Q4 2024

BioRestorative Therapies Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings release: Q4 2024

BioRestorative Therapies Transcript: Status Update

Feb 27, 2025, 10:30 AM EST - 1 year ago

BioRestorative Therapies Transcript: Status Update

BioRestorative Therapies Press release: Status Update

Feb 27, 2025, 10:30 AM EST - 1 year ago

BioRestorative Therapies Press release: Status Update

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 27, 2025, 9:45 AM EST - 1 year ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 26, 2025, 8:15 PM EST - 1 year ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Feb 20, 2025, 8:30 AM EST - 1 year ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Dec 5, 2024, 6:45 AM EST - 1 year ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

BioRestorative Therapies Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q3 2024

BioRestorative Therapies Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioRestorative Therapies Earnings release: Q3 2024

BioRestorative Therapies Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioRestorative Therapies Quarterly report: Q3 2024

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Nov 5, 2024, 7:10 AM EST - 1 year ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 3, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Sep 19, 2024, 6:55 AM EDT - 1 year ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

BioRestorative Therapies Quarterly report: Q2 2024

Aug 13, 2024, 10:00 AM EDT - 2 years ago

BioRestorative Therapies Quarterly report: Q2 2024

BioRestorative Therapies Earnings release: Q2 2024

Aug 13, 2024, 10:00 AM EDT - 2 years ago

BioRestorative Therapies Earnings release: Q2 2024

BioRestorative Therapies Proxy statement: Proxy Filing

Aug 8, 2024, 8:00 AM EDT - 2 years ago

BioRestorative Therapies Proxy statement: Proxy Filing

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jul 23, 2024, 7:10 AM EDT - 2 years ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 27, 2024, 7:40 AM EDT - 2 years ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 17, 2024, 7:05 AM EDT - 2 years ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 13, 2024, 7:00 AM EDT - 2 years ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

Jun 4, 2024, 8:50 AM EDT - 2 years ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 24, 2024, 7:45 PM EDT - 2 years ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 15, 2024, 9:00 AM EDT - 2 years ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 14, 2024, 4:10 PM EDT - 2 years ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

May 8, 2024, 7:30 AM EDT - 2 years ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 4:15 PM EDT - 2 years ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

MGroup
MGroup Sep. 12 at 4:02 PM
$BRTX with Silva gone, who’s working here ? The preliminary results from BRTX-100 were very encouraging, but who’s running the show ?? And where is Kaos ??
1 · Reply
Dsradoff720
Dsradoff720 Sep. 12 at 10:11 AM
$BRTX the best thing I think now that can happen is they completely shift to ai or something crazy but I assume that would require issuing a massive amount t of shares to the company they would merge with.
0 · Reply
MGroup
MGroup Sep. 11 at 6:26 PM
$BRTX some sort of earnings report 9/14. I would much prefer somebody giving an explanation of what is actually going on
0 · Reply
wren2016
wren2016 Sep. 11 at 4:06 PM
$BRTX Another r/s will never get my money back.
0 · Reply
Dsradoff720
Dsradoff720 Sep. 11 at 2:44 PM
$BRTX Silva is gone? Pretty messed up. If they don’t have a plan this could be really rough. They have active patients and Silvas name is on their parents too I believe. So how does that work? The price isn’t crashing either which is odd so I’m wondering wth is going to happen. Are they going to completely shift? Are they going to fold? We need more info let out.
0 · Reply
Sixty8times
Sixty8times Sep. 10 at 7:15 PM
$BRTX what a pile of crap this has turned out to be. Those of you who were in it early, got smashed with a 4000/1 reverse split and now another reverse split. And that was two years ago. Good luck.
0 · Reply
YouVSYou
YouVSYou Sep. 9 at 7:45 PM
$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 8:09 PM
Today's reverse split results. 3 of 8 closed green today. Part 1 of 2: $AIXI 1 for 7 Previous close $0.4715, $3.3005 split-adjusted Today's high $3.45 (premarket) Today's close $3.26 🔴Down 1.23% $BRTX 1 for 20 Previous close $0.1480, $2.96 split-adjusted Today's high $3.23 Today's close $2.8028 🔴Down 5.31% $CTSO 1 for 20 Previous close $0.3501, $7.002 split-adjusted Today's high $7.44 Today's close $6.85 🔴Down 2.17% $GTBP 1 for 25 Previous close $0.2410, $6.025 split-adjusted Today's high $5.95 Today's close $5.2395 🔴Down 13.04%
1 · Reply
MGroup
MGroup Sep. 8 at 6:04 PM
$BRTX outstanding is 1.4 millionish. Never owned a stock with such a tiny float. This should get real interesting from a technical standpoint. And BRTX-100 is a viabe stem cell product. Seems we forgot about stem cells in biotech. It's all small molecule now days.
1 · Reply
TheBigDawgRoman
TheBigDawgRoman Sep. 8 at 1:53 PM
$BRTX holding at 10 dollars!!
0 · Reply
gobuckeyes21
gobuckeyes21 Sep. 8 at 1:48 PM
$BRTX under a dollar in a month or less.
1 · Reply
TwongStocks
TwongStocks Sep. 8 at 11:34 AM
$AIXI $BRTX $CTSO $GTBP $LRHC Are among the nine NASDAQ stocks with reverse splits today. Full details in quoted post. Trading will resume at 9:00am ET with the RS in effect.
0 · Reply
MGroup
MGroup Sep. 6 at 4:12 PM
$BRTX guess we open somewhere around $3 on Tuesday ??
2 · Reply
MGroup
MGroup Sep. 5 at 2:17 PM
$BRTX my account already reflects the reverse split in share count
0 · Reply
TwongStocks
TwongStocks Sep. 4 at 8:09 PM
Nine NASDAQ stocks with reverse splits on Tuesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Tuesday morning. I'll have to split this into two parts. Part 1 of 2: $AIXI 1 for 7. They do not have any recent SEC filings that confirm the current number of ADS outstanding. Unable to provide estimated post-RS share count without up to date data. $BRTX 1 for 20. Will reduce outstanding shares from approx 27.62m to approx 1.38m. $CTSO 1 for 20. Will reduce outstanding shares from approx 63.02m to approx 3.15m. $GTBP 1 for 25. Will reduce outstanding shares from approx 45.11m to approx 1.80m. $LRHC 1 for 6. Will reduce outstanding shares from approx 3.4m to approx 569k.
0 · Reply
gobuckeyes21
gobuckeyes21 Sep. 4 at 12:12 AM
$BRTX what a dumpster fire 🔥 Tried warning you all.
1 · Reply
Rahmmy
Rahmmy Sep. 3 at 7:47 PM
$BRTX 1 for 20 might not be enough to keep it over $1.
1 · Reply
TwongStocks
TwongStocks Sep. 3 at 7:27 PM
$BRTX Equity Corporate Actions Alert #2026 - 636 Information Regarding the Reverse Stock Split and CUSIP Number Change for BioRestorative Therapies, Inc. (BRTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-636 BioRestorative Therapies, Inc. (BRTX) will effect a one-for-twenty (1-20) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, September 8, 2026. In conjunction with the reverse split, the CUSIP number will change to 090655705.
0 · Reply
Rahmmy
Rahmmy Sep. 3 at 12:02 PM
$BRTX Summary BioRestorative Therapies is executing a substantial executive and governance overhaul. The company appointed Mika Grasso as Interim Chief Executive Officer and Anna Skowron as fractional Chief Financial Officer. These appointments, effective in late August 2026, coincide with a transition toward a consultant-based executive model. Mika Grasso, aged 29 and a director since June 2026, was originally appointed as a designee of Bowery Group LLC, a lender to the company. His appointment as Interim CEO follows his tenure on the Audit Committee. Anna Skowron joins on a fractional basis, providing services through BPC Consulting Ltd. This management structure, relying on external consulting agreements rather than full-time employment, may reflect a strategic effort to manage cash burn or address operational needs with external resources. The company simultaneously dismissed CBIZ CPAs P.C. as its independent auditor, effective August 28, 2026, and engaged Bush & Associates CPA.
2 · Reply
focafoca99
focafoca99 Sep. 3 at 8:14 AM
$BRTX executed a 1-for-20 reverse stock split, consolidating shares and reducing the share count to about 1.38 million.
1 · Reply
gobuckeyes21
gobuckeyes21 Sep. 2 at 10:03 PM
$BRTX $BRTX lol rinse and repeat. The scam strikes again and will fleece a whole new group of people. The “trials” have been in the works for 6 years 🤡
1 · Reply
TwongStocks
TwongStocks Sep. 2 at 9:48 PM
$BRTX 1 for 20 reverse split. https://www.globenewswire.com/news-release/2026/09/02/3355556/0/en/biorestorative-therapies-announces-reverse-stock-split.html The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705.
2 · Reply